Provided herein are natural killer (NK) cells with increased, modified or deleted extracellular matrix (ECM) receptors, and methods of making and using the same for cancer immunotherapy, and treatment of chronic infections, inflammation, autoimmune diseases, or transplant rejection.
Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.
Systems and methods are provided for patient monitoring and/or treatment. The system may include one or more sensors configured to measure electroencephalogram (EEG) and electrodermal signals of a patient subject to at least one anesthetic agent and at least one analgesic agent during an operative medical procedure. The system can also include a processor, operably coupled to the one or more sensors. The processor is configured to receive the EEG and electrodermal signals and, using the EEG or electrodermal signals, generate a report indicating the nociceptive state of the patient in real-time during the operative medical procedure while the patient is subject to the at least one anesthetic and a pain management plan based on desired post-operative outcomes..
A61B 5/316 - Modalities, i.e. specific diagnostic methods
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
4.
HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING
An injectable nanoparticular formulation and method of use thereof for treating non-compressible hemorrhage or internal bleeding has been developed. The formulation includes two interactive components, one a targeting nanoparticle with a polypeptide sequence that binds to a cell present at a site of injury, and the other a crosslinking nanoparticle with a bioorthogonal click-crosslinking group.
Improved compositions and methods for generating chondrocytes and cartilage tissues from human pluripotent stem cells are provided. Methods include use of one or more of FGF agonist,cAMP agonist, and TGFβ agonist to induce chondrogenesis in monolayer culture. Articular cartilage tissues generated using the methods have zonal organization similar to native cartilage tissue including surface chondrocytes and intermediate zone chondrocytes, with increased extracellular matrix components consistent with native cartilage tissue. These biochemical and mechanical properties make the cartilage tissue particularly suited for tissue implants in vivo.
Systems and methods described herein can facilitate in vivo characterization of soft tissue, such as within a colon or other areas of a gut, by providing one or more of a geometric variable or a biomechanical response variable. For example, a tissue characterization system can include a control system, a pressure transducer, and a catheter. The system can measure pressure and diameter data of a soft tissue region or interest. The pressure and diameter data can be analyzed to provide a gut stiffness index that corresponds to various characterizations of the region of interest, such as an extent of gut fibrosis, a severity of mucosa damage, or an infiltration of immune cells
The disclosure is directed, in part, to novel drug-responsive T cell factors providing temporal and/or spatial control over T cell (e.g., CAR T cell) activation and/or proliferation, T cells comprising the T cell factors, nucleic acid encoding the T cell factors, and methods for using and producing the same.
C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
LIG1POLD1 XRCC1 LIG1 LIG1 LIG1 loss was also associated with higher chromosomal instability index (CIN) and poor prognosis in other cancer types, demonstrating that deletion of lagging- strand synthesis components has broad clinical significance.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
9.
VAGINAL LIVE BIO-THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
The invention features compositions and methods that are useful for determining the fraction of tumor-derived DNA (tumor fraction; TF) in cell free DNA (cfDNA). The methods involve calculating the fraction of tumor-derived DNA in the cfDNA using a combination of copy number alteration data and fragment length distribution data.
11.
PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF
Described herein are pancreatic ductal adenocarcinoma (PDAC) signatures and methods of detecting the same in a sample from a subject. Also described herein, are methods of methods of diagnosing, prognosing, and/or treating PDAC in a subject that can include detecting one or more of the PDAC signatures.
12.
NEURAL PROGENITOR CELL COMPOSITIONS AND METHODS OF USING THE SAME
The claimed invention is directed to compositions including adipose tissue-derived, for example, subcutaneous adipose tissue-derived or visceral adipose tissue-derived neuronal progenitor cells, and methods for the production and uses thereof.
The present disclosure relates to the use of a contact-type patch in a staining process. An exemplary method for quenching a fluorophore present in a biological sample includes contacting a surface of a quenching patch including a polymer-containing substrate and a quenching agent disposed within the substrate, with the biological sample.
A compact, portable linear scanning x-ray system includes a physically uncoupled x-ray source and x-ray detector that are each translatable along different respective scanning trajectories. The scanning trajectories may be linear scanning trajectories, which may be parallel linear scanning trajectories. The x-ray source and x-ray detector can be independently moveable. A controller aligns the x-ray source with the x-ray detector and synchronously moves the x-ray source and x-ray detector to obtain an image of an object. Artificial intelligence algorithms can be used to provide for automatic alignment and/or movement of the x-ray source and x-ray detector, which may be based on positioning sensors located on the x-ray source, the x-ray detector, or both.
Systems and methods are provided for weight bearing images. A pressure sensor has a surface for receiving the feet of a patient while the patient is standing and generating pressure distribution map having a first region associated with a first foot of the patient and a second region associated with a second foot of the patient. An imager captures an image of a region of interest associated with the patient while the patient is standing on the sensor interface. A predictive model receives a representation of the first region and a representation of the second region and determines a value representing a stance of the patient. An output interface provides the value representing the stance of the patient to one of a display, the imager, and an image post-processing model.
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Henary, Maged
Choi, Hak Soo
Kashiwagi, Satoshi
Abstract
The present invention is directed to squaraine fluorophores, methods of making squaraine fluorophores, and methods of using squaraine fluorophores. In some embodiments, squaraine fluorophores can be used as imaging agents, for example for imaging cancer. In some embodiments, the squaraine fluorophores can be used to guide surgical tumor resection.
Described herein are methods comprising using measurements of perioperative plasma concentrations of Tau-PT217 and/or Tau-PT181 to predict which subjects are likely to develop postoperative delirium, and to thereby identify which patients are most likely to benefit from interventions to reduce risk or mitigate the severity or consequences of postoperative delirium.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
18.
AN ULTRA-FLEXIBLE MINIATURE OPTICAL COHERENCE TOMOGRAPHY CATHETER AND IMAGING METHOD FOR ENDOMICROSCOPY OF THE INNER EAR
An imaging tool, including: a drive shaft including a proximal end and a distal end; an optical waveguide including a proximal end and a distal end, the proximal end of the optical waveguide being disposed within the proximal end of the drive shaft, and the distal end of the optical waveguide extending beyond the distal end of the drive shaft; and an optical probe head coupled to the distal end of the optical waveguide.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
Systems and methods for a coupling a percutaneous device. The system can include a first coupling that can be configured to connect to a first catheter extending through a percutaneous opening in a patient, a second coupling that can be configured to connect to a second catheter to fluidly connect to the first catheter, and a failure-release that can be configured to automatically disconnect the fluid connection between the first catheter and the second catheter upon the system receiving a force at or above a predetermined threshold to protect the percutaneous opening in the patient from the force.
Systems/techniques that facilitate automated training of machine learning classification for patient missed care opportunities or late arrivals are provided. In various embodiments, a system can access a set of annotated data candidates defined by two or more feature categories. In various aspects, the system can train a machine learning classifier on the set of annotated data candidates, thereby causing internal parameters of the machine learning classifier to become iteratively updated. In various instances, the system rank the two or more feature categories in order of classification importance, based on the iteratively updated internal parameters of the machine learning classifier. In various cases, the system can perform one or more electronic actions based on the two or more feature categories being ranked in order of classification importance.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
The development of new immunoregulatory small molecules represents a significant advance in immunotherapy. Provided herein are compounds, such as compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, and compositions, methods, uses, and kits that may be used in immunotherapy. The compounds provided herein are responsible for immunomodulatory signaling through the TLR2 receptor and are therefore useful for the treatment and/or prevention of various diseases (e.g., metabolic diseases, inflammatory diseases, immune disorders, or proliferative diseases).
A61K 31/688 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
23.
ANALYSIS, SCREENING, AND SELECTION FOR SOLUBLE PROTEIN FUNCTION IN SECRETED PROTEIN CELL LIBRARIES
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
C12N 15/65 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
The present disclosure provides novel methods for treating, preventing, ameliorating, inhibiting and/or delaying the onset of tauopathies. The methods comprise administering to the subject an effective amount of a small molecule peptidomimetic, such as (R)-2-amino-N- ((S)-l-(((S)-5-amino-l-(3-benzyl-l,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6- dimethylphenyl)-l-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Described herein are methods of ablating a cell population using chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Systems and methods are provided that may facilitate the irrigation of an anatomic space. The irrigation system can include a tube manifold, a fluid reservoir, a waste fluid trap and an emulsification system. The emulsification system can be arranged at a distal end portion of the tube manifold and can be configured to be inserted into an anatomic space and emulsify organic material located within the anatomic space.
The present disclosure features systems and methods for isolating target entities (TEs) found in target entity-secondary entity complexes within a biological fluid by exploiting interactions between TE, secondary entities (SEs), and/or engineered surfaces (ESs). TE isolation involves a two-step process in which TE-SE complexes are initially captured using, e.g., size-based approaches or binding interactions between SEs and ESs, and then TEs are specifically released from the captured TE-SE complexes using, e.g., biochemical means, such as disassociating enzymes and/or binding inhibitors, or using physical properties of fluid flow, e.g., flow velocity and/or shear rate.
The subject matter disclosed herein is generally directed to methods and compositions for a single- or multi-pot protocol for the efficient end to end capture of RNAs (inclusive of their poly- A tail or their 3' end). The invention includes the use of capture oligonucleotides containing a 3' non-extendable end and a selectively cleavable base upstream of an oligo-dT or oligo-dN and a 5' sequence containing unique molecular identifiers, and 2) a deoxyuracil glycosylase that acts only on a deoxyuracil present in a DNA:DNA duplex or DNA/RNA heteroduplex. The invention also includes the use of a dual template switching mechanism..
The invention provides molecular classifiers for use in the characterization and diagnosis of lung cancer and methods of selecting and treating subjects with appropriate personalized cancer treatments, including but not limited to CDK4/6 inhibitors, c-Met inhibitors, PD-1/PD-L1 inhibitors and combinations thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
31.
PARALLEL ANTIBODY ENGINEERING COMPOSITIONS AND METHODS
The present invention discloses high-throughput methods for the creation of antibodies or antigen-binding fragments that can bind to single or multiple targets. Also disclosed are methods for using one or more antibodies or antigen-binding fragments to detect cognate binding partners in various types of samples.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for segmentation of vessels of interest from image data. The image analysis provides for guidance for insertion of a cannulation system into a subject which may be accomplished by a non-expert based upon the guidance provided. The guidance may include an indicator or a mechanical guide to guide a user for inserting the vascular cannulation system into a subject to penetrate the vessel of interest.
A system and method for clinical disorder assessment are disclosed. The method and the medical assessment system using the method include: obtaining sensor data indicative of movement of a user; generating a movement dataset by reducing dimensions of the sensor data; generating a plurality of submovement datasets based on the movement dataset; extracting a movement feature from a first subset of the plurality of submovement datasets; analyzing the movement feature from the first subset of the plurality of submovement datasets to a reference to determine a potential clinical disorder of the user; and generating a report that includes an indication and severity of the potential clinical disorder of the user. Other aspects, embodiments, and features are also claimed and described.
mnn, as well as methods of making and using such compositions. Also described herein are methods of treating cancer using such compounds with a combination therapy.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
35.
CRISPR-ASSOCIATED TRANSPOSASES AND METHODS OF USE THEREOF
Described herein are improved CRISPR-associated transposases (CASTs), including homing endonuclease-assisted large-sequence integrating CRISPR-associated transposases (CAST) complexes and methods of use thereof, and other strategies to improve the activities of natural and engineered CASTs.
The invention features methods for the identification of genomic aberrations in circulating tumor cells (CTCs) isolated from peripheral blood. In various embodiments of the disclosure, the methods involve isolation of a small number of purified circulating multiple myeloma cells, purification of genomic DNA from the cells, and sequencing of the genomic DNA.
The invention relates to a monomeric immunogen comprising one receptor binding domain of a Coronavirus spike protein, wherein the receptor binding domain includes at least 4 non-native, N -linked, glycosylation sites.
Computer-implemented methods, computer program products, and systems determine an omics profiles of a cell using microscopy imaging data. In one aspect, a computer-implemented method determines an omics profiles of a cell using microscopy imaging data by a) receiving microscopy imaging data of a cell or a population of cells; b) determining a targeted expression profile of a set of target genes from the microscopy imaging data using a first machine learning model, the target genes identifying a cell type or cell state of interest; and c) determining a singlecell omics profile for the population of cells using a second machine learning algorithm model. The targeted expression profile and a reference single-cell RNA-seq data set are used as inputs for the second machine learning model.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
39.
COMBINATION THERAPY WITH ANTI-TROP-2 ANTIBODIES AND PARP INHIBITORS
The present disclosure relates to a combination therapy with an anti-Trophoblast cell surface antigen 2 (Trop-2) antibody drug conjugate (anti-Trop-2 ADC) and a poly (ADP-ribose) polymerase inhibitor (PARPi) using a staggered dosing schedule. The ADC preferably incorporates an inhibitor of type I topoisomerase, such as SN-38 or DXd. The ADC is preferably administered prior to the PARPi in each cycle of the staggered dosing schedule. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. The schedules and dosages show efficacy against tumors, while exhibiting only manageable toxicity to normal tissues. Use of staggered dosing of an anti-Trop-2 ADC and a PARPi can reduce toxicity, for example relative to alternative dosing schedules involving daily administrations of the PARPi on each day of a cycle.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The invention features pseudotyped viral particles (e.g., lentiviral or gammaretroviral particles) and compositions and methods of use thereof, where the viral particles comprise a VHH domain.
C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
In vivo approaches for altering cells would benefit from effective methods for retargeting vectors to be specific for particular cell types in a subject. However, such methods remain inefficient and/or poorly developed. Thus, there is a need for improved methods for in vivo delivery of vectors to a target cell. The invention features pseudotyped viral particles (e.g., lentiviral or gammaretroviral particles) and compositions and methods of use thereof, where the viral particles comprise a VHH domain.
C12N 7/04 - Inactivation or attenuation; Producing viral sub-units
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The invention features a method including characterizing a white blood cell sample from a patient using cytometry (e.g., CyTOF); wherein a deficiency in regulatory or suppressive immune cells and increased activated immune cells in the sample, relative to a healthy sample, indicates that the patient has amyotrophic lateral sclerosis (ALS).
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
The present application provides compounds that are proteolysis targeting chimeras containing a celastrol-based ubiquitin ligase targeting moiety. Methods of using these compounds for treating various diseases, such as neurodegenerative diseases and cancer, are also provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
44.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS
Compounds, pharmaceutical compositions, and methods of use of said compounds and pharmaceutical compositions for treating or preventing a microbial infection or for inducing antimicrobial activity against a microbial infection.
The disclosure is directed to anti-mesothelin antibody reagents, nucleic acids encoding said reagents, cells comprising said antibody reagents and nucleic acids, and methods of treating cancer comprising administering the aforementioned to a subject.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
46.
PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE
The invention features compositions and methods useful for targeting and activating translation, for example, non-canonical translation, in cancer cells.
144 are each independently H, hydroxyl, halogen, lower alkyl or lower alkoxy; as well as related pentamidine analogs and their use to inhibit bacterial growth and treat bacterial infection.
C07C 257/18 - Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
C07D 211/22 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms by oxygen atoms
C07D 213/60 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
49.
ANTI-MESOTHELIN CAR T CELLS SECRETING TEAMS AND METHODS OF USE THEREOF
The present disclosure relates to mesothelin chimeric antigen receptors (CARs), T cell engaging molecules (TEAMs), anti-mesothelin-CAR T cells optionally comprising TEAMs, and methods of use thereof.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided herein are methods of treating a thrombotic microangiopathy (TMA) in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that binds to and inhibits MBL2 and an antibody that binds to and inhibits FXIa. In some embodiments, the antibody that binds to and inhibits MBL2 is 3F8 or an analogue thereof, and/or, the antibody that binds to and inhibits FXIa is 3G3 or an analogue thereof.
The present disclosure provides a method for treating symptoms of Prader-Willi Syndrome (PWS). Hie method includes administering a probiotic composition to the subject. The present disclosure further includes a. method, for determining an efficacy of a probiotic composition to treat PWS in a subject. The present disclosure further includes a kit. The kit includes a probiotic composition for oral administration and a detection molecule for the detection one or more microorganisms.
An atraumatic catheter is provided. The catheter has an inflation section and a drainage section. At least one balloon is disposed in the inflation section and is offset from the central longitudinal axis of the catheter shaft. The length of the balloon in an actuated state is greater than the length of the balloon in a non-actuated state while the width of the balloon remains substantially the same in an actuated state and a non-actuated state.
A method and system for assessing tissue to determine a presence or absence of cancer cells. The method includes acquiring fluorescence lifetime (FLT) data from tissue and processing the FLT data to determine a FLT signal at each of a plurality of locations across the tissue. The method also includes determining FLT data at any of the plurality of locations above a threshold indicative a presence of cancer cells and generating a report indicating any of the plurality of locations above the threshold as indicative the presence of cancer cells.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
54.
COMPOSITIONS AND METHODS FOR TREATMENT OF OBSTRUCTIVE SLEEP APNEA
Disclosed herein are methods that allow for treating sleep apnea by removing adipose tissue and increasing collagen production in a patient's upper airways by injecting ice slurry comprising ingredients such as sterile water, a biocompatible surfactant such as glycerol, and saline into the target area.
THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
Herrmann, Franziska Elena
Le, Quang Huy
Seither, Peter
Medoff, Benjamin D
Moutinho Dos Santos, Daniela Vanessa
Yang, Yang
Abstract
Methods of treating and preventing fibrosis, and diseases/disorders characterised by fibrosis, through ADAMTS14 inhibition are disclosed, as well as agents for use in such methods.
The subject matter disclosed herein relates to utilizing the silhouette of an individual to measure body fat volume and distribution. Particular examples relates to providing a system, a computer-implemented method, and a computer program product to utilize a binary outline, or silhouette, to predict the individual's fat depot volumes with machine learning models.
An access device includes an access assembly for percutaneously accessing an anatomical space in a patient. An aspiration assembly is operable to generate negative pressure in a fluidic channel of the device. The fluidic channel places the access assembly in fluid connection with the aspiration assembly. A fluid tube has a first tube end connected to the access assembly, a second tube end connected to the aspiration assembly, and a tube body. The tube body defines a manometer tube portion spaced apart from both the first and second tube ends. The manometer tube portion acts as at least part of a manometer when the device is in a manometer mode. The manometer tube portion has adjacent first and second manometer tube ends and an inflection point substantially reversing the direction of the manometer tube portion at a location spaced apart from both the first and second manometer tube ends.
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61M 25/06 - Body-piercing guide needles or the like
The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A system for evaluating a subject, including: a processor in communication with a carbon monoxide (CO) detector, and a memory in communication with the processor having stored thereon a set of instructions which, when executed by the processor, cause the processor to: receive, from the CO detector, a measure of CO in a subject suspected of having at least one of autism spectrum disorder (ASD), autoimmunity, or inflammation; obtain a level of at least one biomarker associated with the subject based on receiving the measure of CO in the subject; and generate a report based on obtaining the level of the at least one biomarker.
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/08 - Measuring devices for evaluating the respiratory organs
A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, compositions comprising same, and methods of using the compounds and compositions to treat various cancers.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Disclosed herein are methods and devices for use in early detection of Richter's Syndrome. The methods include sequencing a panel of regions in cell-free DNA molecules and detecting one or more markers that are indicative of Richter's Syndrome.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
63.
TUMOR AVATAR VACCINE COMPOSITIONS AND USES THEREOF
Disclosed herein are methods of eliciting an anti-cancer immune response by administering tumor-associated antigens, cells containing tumor-associated antigens, and/or nucleic acids encoding tumor-associated antigens, inducing immunogenic cell death in the cells expressing or containing the tumor-associated antigens, and optionally generating hyperactivated dendritic cells. Expression of tumor-associated antigens in a separate anatomical site generates a tumor avatar, which mimics the antigenic, but not immunosuppressive, environment of the tumor, with the generation of hyperactivated dendritic cells enhancing antigen presentation to elicit a robust anti-tumor T cell and antibody response. Also provided are compositions and kits containing nucleic acids and other components for use in the methods provided herein.
Disclosed are methods of identifying a cross-modal feature from two or more spatially resolved data sets, the method including: (a) registering the two or more spatially resolved data sets to produce an aligned feature image including the spatially aligned two or more spatially resolved data sets; and (b) extracting the cross-modal feature from the aligned feature image.
A method for detecting inflammatory activity, including: providing a catheter including a near-infrared fluorescence (NIRF) imaging system configured to perform NIRF imaging and an optical coherence tomography (OCT) imaging system configured to perform structural imaging; introducing a near-infrared fluorescent cathepsin-activatable imaging agent into a blood vessel; placing a distal end of the catheter within the blood vessel; obtaining, using the OCT imaging system, structural images of an atherosclerotic plaque within the blood vessel; obtaining, using the NIRF imaging system, NIRF images of the atherosclerotic plaque within the blood vessel; detecting the near-infrared fluorescent cathepsin-activatable imaging agent in the NIRF images; and identifying inflammation within the atherosclerotic plaque based on detecting the near- infrared fluorescent cathepsin-activatable imaging agent in the NIRF images.
A bone surgical apparatus provides an improved method and apparatus to manipulate the curvature of the spine. The bone surgical apparatus can include a connector comprising a rod having a first end section and a second end section wherein the rod is dimensioned to connect a pair of pedicle screws, and a fastener attached to the rod wherein the fastener comprises a head including spaced apart walls defining a recess for receiving an alignment rod.
A cellular coding construct uniquely codes a cellular entity and includes a laser particle and a structurally coded oligonucleotide. The structurally coded oligonucleotide and the laser particle have a physical association with each other and are configured for physical association with the cellular entity and also configured for distinctive identification of the cellular entity.
The present application provides oxazoles-containing compounds, or a pharmaceutically acceptable salt thereof, that are 12/15-LOX inhibitors. Pharmaceutical compositions and methods of using these compounds for treating various conditions wherein 12/15-LOX is implicated (such as stroke) are also provided.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
69.
USING THE DYNAMIC FORWARD SCATTERING SIGNAL FOR OPTICAL COHERENCE TOMOGRAPHY BASED FLOW QUANTIFICATION
An apparatus for measuring a blood flow parameter in a blood vessel, including: an interferometric data collection apparatus including a light source and a sensor coupled to a controller, the controller being configured to: direct the light source toward a proximal side of a blood vessel; obtain interferometric data from a tissue adjacent to and outside of a distal side of the blood vessel opposite the proximal side; determine a signal modulation rate based on the interferometric data; and estimate a blood flow parameter in the blood vessel based on the signal modulation rate.
An apparatus for transesophageal echo-oximetry, including: an insertion tube having an optical fiber disposed therein; a probe disposed at an end of the insertion tube, the probe including: an acoustic transducer, and a reflector aligned with the acoustic transducer and the optical fiber; a controller in communication with the acoustic transducer, the controller configured to: generate an ultrasonic image of a sample using the acoustic transducer and the reflector, direct light from the optical fiber toward the reflector and into the sample, collect photoacoustic signals from the sample based on the directed light using the acoustic transducer and the reflector, and determine a blood oxygenation level in the sample based on the photoacoustic signals.
A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
Provided herein are methods and immune biomarkers that identify progression and treatment options for hematological malignancies (e.g., smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), or multiple myeloma (MM)). Also provided are materials and methods for the prognosis, staging, and monitoring of SMM, MGUS, or MM based on the presence of the immune biomarkers in a sample (e.g., a blood sample or a bone marrow sample), as well as methods for monitoring the progression of SMM, MGUS, or MM, determining the efficacy of a therapeutic agent, determining a treatment for SMM, MGUS (e.g., before progression to MM), or MM, and/or treating SMM, MGUS, or MM. The methods provided herein provide several advantages over invasive biopsies.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
A magnetic field monitoring system can include a host system that generates a magnetic field. The magnetic field monitoring system can include a plurality of sensor assemblies disposed apart from each other within the host system. Each of the plurality of sensor assemblies can include a coil wound around a sample and an integrated circuit coupled with the coil. The integrated circuit can perform one or more MR measurements of the sample using one or more pulse sequences.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
The present application provides compounds and methods for identifying a modulator of a protein of interest using TR-FRET donor attached to the protein of interest and a tracer containing TR-FRET acceptor. Iterations of this compound may also includes attachment of an ATP-binding moiety, an amino acid, and/or a fluorophore.
G01N 21/62 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
Provided herein are methods for reducing pigmentation, comprising administering to the skin, hair, and/or eyes of a subject an effective amount of an nicotinamide nucleotide transhydrogenase (NNT) activator and/or Mitofusin 2 (MFN2) activator, also provided are compositions for use in a method of decreasing pigmentation in the skin, hair, and/or eye of a subject, said method comprising administering the composition to the skin, hair, and/or eye of the subject.
The present application provides radioisotope-containing compounds that are, e.g., mGluR2 modulators. Methods of imaging brain of a patient, as well as methods of diagnosing and monitoring treatment of psychiatric or neurological disorders in which mGluR2 is implicated, are also disclosed.
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
76.
BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF
Bifidobacterium longum subspeciesBifidobacterium longum subspeciesBifidobacterium longum subspeciesBifidobacterium longum subspecies microorganisms and formulations thereof, such as in an infant and/or young child.
The present application relates to extensively hydrolysed protein, and compositions comprising extensively hydrolysed protein, for use in reducing the risk of intestinal inflammation, reducing the risk of intestinal tissue damage, and/or improving gut barrier function, in an infant.
The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a breast cancer or a pancreatic cancer). More specifically, the invention concerns the treatment of patients having cancer for the therapeutic inhibition of cancer cell growth and metastasis with an anti- Cadherin 11 monoclonal antibody with specific monoclonal antibody clones 23C6 or 3H10.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
79.
APPARATUS AND METHODS TO ENHANCE SIGNAL TO NOISE RATIO IMAGING PERFORMANCE IN OPTICAL COHERENCE TOMOGRAPHY
An optical coherence tomography system which is capable of operating in two or more optical bandwidth configurations for the purpose of trading off between high resolution imaging and high signal-to-noise ratio imaging, wherein the later enables deeper imaging depth. The system and associated methods allow for both high resolution, shallow penetration depth and low resolution, deep penetration depth optical coherence tomography imaging to be performed using a single light source. Methods and apparatus are described that allow a single system to dynamically switch between modes, or to operate in a hybrid mode that achieves a balance between resolution and SNR/depth of penetration.
The present invention relates generally to the use of an ERK1/2 inhibitor in combination with a B-Raf inhibitor that is encorafenib or dabrafenib for treating cancer, specifically solid tumors.
Systems and methods for generating a trajectory model characterizing a disease state and using the trajectory model in determining a recommended treatment. In one aspect, a method includes obtaining patient data, in which the patient data includes clinical laboratory results of a patient with a disease state; processing the patient data such that the clinical laboratory results are normalized by patient-specific or cohort-specific baseline levels of the clinical laboratory results; and applying a trajectory model to the processed patient data to identify a likelihood of an adverse outcome of the patient, in which the trajectory model characterizes the disease state by a recovery trajectory in a phase-plane of one or more variables.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present application provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of using said compound and said compositions for treating neurodegenerative diseases, are also provided.
A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The present invention provides antigen binding domains that bind phosphorylated versions of CREB-regulated transcription coactivator 3 (CRTC3), polynucleotides encoding them, vectors, host cells, and methods of making and using them. Where CRTC3 comprises at least one set of complementarity determining regions (CDRs), including heavy chain complementarity determining region HCDR1, HCDR2, and HCDR3.
Methods for generating pre-epicardial cells (PECs) and/or cardiomyocytes (CMs) useful for cardiac tissue engineering, compositions comprising the cells, and methods of use thereof.
Provided herein are compositions and methods for enhancing the activity of Stimulator of Interferon Genes (STING) with one or more agents for inhibiting the activity of one or more negative regulators of STING, including DNAJC13 and ESCRT.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
86.
SMALL MOLECULE INHIBITORS OF FORMATION OF NEUTROPHIL-DERIVED EXTRACELLULAR TRAPS (NETOSIS) AND USES THEREOF
Aspects of the present disclosure provide methods for treating allergic inflammatory diseases, such as allergic asthma and atopic dermatitis, using inhibitors of matrix metalloproteinase 13 (MMP13) such as small molecule inhibitors of MMP13.
A method for generating a B-mode image of a sample, including: obtaining a plurality of M-mode frames from the sample using a probe; combining the plurality of M-mode frames into a montage, the montage comprising a plurality of A-lines corresponding to the respective plurality of M-mode frames; comparing adjacent A-lines of the montage to identify at least one pair of correlated A-lines; and removing one of the at least one pair of correlated A-lines from the montage to generate a B-mode image.
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
The invention features a method for treating graft versus host disease in a human, including administering to said human a therapeutically effective amount of a cell including a chimeric antigen receptor (CAR) which is specifically directed against an immune checkpoint molecule.
Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with high sensitivity and specificity in detecting fibrogenesis, for example, in rodent models and human fibrotic tissues.
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
A61K 49/06 - Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
91.
TARGETING EXTRACELLULAR MATRIX PROTEINS TO REGULATE NK CELL FUNCTION IN PERIPHERAL TISSUES
Elucidating the mechanism that underlies tissue-specific NK cell responses will have major implications in cancer immunology, transplant biology and virology. Provided herein are compositions and methods for of treating a subject who has a solid tumor or who has a viral infection, or promoting cytotoxicity of natural killer (NK) cells in a subject, using (i) blocking antibodies to ECM components and/or (ii) inhibitors of collagen deposition or production.
The present disclosure relates to a perfusate, a storage solution, or a recovery solution having an apoptosis inhibitor. Also disclosed are various uses, including preserving a biological tissue sample and mitigating ischemia-reperfusion injury in such samples.
A fluidic transistor comprising: a flow region configured to transport a first fluid; a gate region configured to contain a second fluid; and a deformable region disposed between the flow and gate regions, wherein the deformable region is configured to induce flow-limitation as the first fluid is transported within the flow region.
A system and method are provided for providing a collaborative annotation platform. The method includes enabling access to a collaborative annotation project associated with at least one medical image. The method also includes receiving crowdsourced annotations associated with the at least one medical image from a set of annotators. The method also includes evaluating the crowdsourced annotations and generating an annotation record associated with the at least one medical image based on the evaluation of the crowdsourced annotations.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
96.
ANIMAL MODEL HAVING HOMOLOGOUS RECOMBINATION OF MOUSE PTH1 RECEPTOR
New transgenic non-human animals comprising human Parathyroid Hormone 1 Receptor (hPTHIR), and methods of producing the same; new assays and screening techniques to evaluate the hPTHIR; and methods and transgenic animals to evaluate the response of hPTHIR to one or more candidate agents.
Described herein are capsid peptides that mediated efficient AAV transduction of the brain vasculature, mainly endothelial cells and pericytes, as well as smooth muscle cells, compositions (including AAV), and methods of using the same. Embodiments of the invention encompass AAV capsid proteins comprising an amino acid sequence that comprises at least four, at least five, or at least six contiguous amino acids from the sequence PRPPSTH (SEQ ID NO: 1); MAEPGAR (SEQ ID NO: 2); SQDPSTL (SEQ ID NO: 3); or MLYADNT (SEQ ID NO: 4).
A system for analyzing a body part of a subject includes a sensor interface having a surface for receiving the body part. A light source emits light having multiple wavelengths within the sensor interface to be reflected by the body part interacting with the surface. An imaging system captures images of the reflected light. A computing device generates a pressure distribution map of the body part on the surface based on the images.
e.g.e.g.e.g.e.g.e.g.e.g., a subject having cancer, graft-versus-host disease (GVHD), or an autoimmune disease. Expression of the pore-forming protein can be induced to promote destruction of immune cells expressing CIRB, CIRB21, CIRB28, or a combination thereof.
An implantable laminoplasty device is provided that can be used in minimally invasive surgery. The device includes a main housing with an inner housing slidably receivable by an outer housing. A gear is disposed in the main housing and engageable with a gear rack of the inner housing to adjust the length of the main housing. The gear defines an aperture configured to accept a tool to translate rotational movement into linear motion. A lock is slidably disposed in the main housing sized and configured to fix the length of the main housing when the desired length is achieved by slidable translation of the inner housing in the outer housing. The device also includes a laminar shelf portion and a lateral mass connection portion defining bone screws and both being hingedly connected to the main housing.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
patents
